Home/Pipeline/SRB21 (anti-HER3-HER2 bispecific)

SRB21 (anti-HER3-HER2 bispecific)

Solid Tumors

LicensedLicensed

Key Facts

Indication

Solid Tumors

Phase

Licensed

Status

Licensed

Company

SunRock Biopharma

About SunRock Biopharma

SunRock Biopharma is a private, preclinical-stage biotech focused on developing novel antibodies for oncology, with a core expertise in targeting chemokine receptor CCR9 and the HER3 (ERBB3) pathway. The company has established a pipeline of mono- and bi-specific antibodies, with several HER3-targeting assets already licensed to Debiopharm, providing non-dilutive funding and validation. SunRock's strategy centers on addressing tumor metastasis and therapy resistance, positioning it in the competitive but high-value oncology biologics space.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed